Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 17, 2008

Thermo Fisher Scientific Takes Over Affinity BioReagents to Bolster Proteomics Offerings

  • Thermo Fisher Scientific reports the acquisition of Affinity BioReagents to complement its protein research efforts. The company will be integrated into Thermo Fisher’s analytical technologies segment.

    With over 35,000 reagents, Affinity BioReagents reportedly had revenues of approximately $6 million in 2007. The firm’s reagents are mostly monoclonal and polyclonal antibodies. The company also provides recombinant proteins and custom antibody-production services.

    “This acquisition enhances our extensive antibody portfolio, which will drive growth as we combine these reagents with our current proteomics offerings to create end-to-end solutions for widely used protein-research applications,” says Marijn E. Dekkers, president and CEO of Thermo Fisher Scientific.  These applications include Western blotting, ELISA, immunohistochemistry, flow cytometry, and mass spectroscopy.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »